Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals is a clinical-stage patient-focused biopharmaceutical company developing novel nucleic acid therapeutic approaches for the treatment of certain cancers and rare diseases. Idera’s immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while our third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA.

Bank Name Idera Pharmaceuticals, Inc.
Stock Exchange NASDAQ
Symbol IDRA
Sector Healthcare
Industry Biotechnology: Biological Products
Country United States
World Region Amarica
Chairman
CEO Mr. Vincent J. Milano
Employees 62
Website www.iderapharma.com
Registered Year 1989

UpdateContent
UpdateContent
UpdateContent